What is the mechanism of action of eribulin?

Eribulin Mechanism of Action

Eribulin is a nontaxane microtubule inhibitor that binds to a distinct site on β-tubulin at microtubule plus-ends, inhibiting microtubule dynamics and causing G2/M phase cell-cycle arrest and apoptosis. 1

Primary Mechanism: Microtubule Plus-End Binding

• Eribulin specifically binds to the plus-ends of microtubules (the growing ends), which distinguishes it from taxanes that stabilize microtubules and vinca alkaloids that destabilize them 1, 2

• This plus-end binding suppresses microtubule dynamic instability rather than causing wholesale polymerization or depolymerization 3, 4

• At the molecular level, eribulin disrupts the End-Binding 1 (EB1) protein complex at microtubule plus-ends, displacing these normal microtubule-stabilizing proteins in a concentration-dependent manner 5

Mitotic Effects Leading to Cell Death

• During mitosis, eribulin suppresses the dynamics of centromeres and their attached kinetochore microtubules, preventing normal spindle tension at kinetochores 6

• This suppression blocks the signal for mitotic checkpoint passage, trapping cells in metaphase arrest 6

• The centromere relaxation rate decreases by 21%, pause time increases by 67%, and overall dynamicity decreases by 35% at therapeutic concentrations 6

• Prolonged mitotic arrest ultimately triggers apoptosis 1, 4

Non-Mitotic Mechanisms with Clinical Relevance

Beyond its direct antiproliferative effects, eribulin exhibits several non-mitotic mechanisms that may contribute to its clinical efficacy:

Vascular Remodeling

• Eribulin induces tumor vasculature remodeling, increasing vascular perfusion and reducing tumor hypoxia 4, 2
• Clinical data confirm increased tumor oxygen saturation following eribulin treatment 4
• Improved perfusion may enhance delivery of subsequent chemotherapy agents 4

Epithelial-to-Mesenchymal Transition (EMT) Reversal

• Eribulin reverses EMT in preclinical models, reducing tumor cell migration, invasion, and metastatic seeding capacity 4, 2
• Clinical specimens show phenotypic changes consistent with EMT reversal 4
• In breast cancer, gene expression shifts from nonendocrine-responsive luminal B to endocrine-responsive luminal A subtypes have been observed 4

Immune Modulation

• Eribulin upregulates E-cadherin expression on tumor cells 7
• This increases CD103+ tumor-infiltrating lymphocytes (both CD4+ and CD8+), which bind E-cadherin via CD103 7
• The resulting T-cell activation increases expression of activation markers (CD38, CD69), cytotoxic molecules (granzyme B, perforin), and immune checkpoint molecules 7
• Both CD4+ and CD8+ T cells are required for eribulin's full antitumor effect in preclinical models 7

Clinical Translation

• The unique mechanism allows efficacy in heavily pretreated patients whose cancers progressed after anthracyclines and taxanes 1

• In leiomyosarcoma and adipocytic sarcomas, 32% and 42% of patients respectively achieved progression-free survival at 12 weeks 3, 1

• In metastatic breast cancer, eribulin demonstrated a 2-month overall survival advantage (13.5 vs 11.5 months) compared to dacarbazine in soft tissue sarcomas 3, 8

Key Distinguishing Features

• Classified as a nontaxane microtubule inhibitor, fundamentally different from taxanes (paclitaxel, docetaxel) and vinca alkaloids 1

• The specific plus-end binding mechanism explains why eribulin retains activity in taxane-resistant tumors that have β-tubulin mutations affecting taxane binding sites 2

• Extended exposure leads to complete microtubule array depolymerization, but therapeutic effects occur at lower concentrations that primarily suppress dynamics 5, 2